Introduction: Data regarding the effectiveness and safety of percutaneous mechanical thrombectomy (PMT) in contemporary routine care are scarce.
Materials And Methods: Consecutive patients undergoing PMT of native lower limb acutely/subacutely occluded arteries were included.
Results: In all, 525 consecutive patients were available for analysis with a mean age of 66.7 ± 10.7 years. Almost two-third (n = 324; 61.7%) were men with acutely (n = 211; 40.2%) or subacutely (n = 314; 59.8%) occluded lesions presenting mostly in Rutherford-Becker category (RBC): 3 (30.3%) and 4 (47.6%). Mean lesion length was 159 mm (range 22-279 mm), with moderate and severe calcification in 119 (23.3%) lesions. PMT was performed solely in 161(27.2%), PMT + balloon angioplasty in 232 (39.1%), provisional stenting in 169 (28.4%), and thrombolysis in 77 (13.9%) interventions. Procedural technical success rate was 97.7%, with improvement in RBC persisting in 74.1% of patients after 12 ± 2.4 months mean time follow-up. Overall 30 days major adverse events (MAEs) was 6.9% with a mortality rate of 1.1%. No death was directly related to the device. After 12 months, a promising overall target lesion revascularization (TLR; 10.1%), non-TLR (6.6%), and major amputation rates (2.3%) were found. One-year mortality was 8%.
Conclusion: Treatment with PMT resulted in clinic and hemodynamic improvement in the majority of patients, thereby reducing the need for thrombolysis in a significant proportion of patients. Prospective studies in this issue are recommended.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0003319716646682 | DOI Listing |
J Surg Res
January 2025
Department of Surgery, Albany Medical Center, Albany, New York; Division of Vascular Surgery, Albany Medical Center, Albany, New York.
Introduction: Surgical site infection (SSI) after lower extremity (LE) bypass surgery is associated with longer length of stay, higher hospital cost, increased morbidity, and even graft loss. Silver impregnated dressings have been used by other surgical subspecialties to decrease SSI with reported success. The National Surgical Quality Improvement Program (NSQIP) published a national expected rate of 7.
View Article and Find Full Text PDFJMIR Cancer
January 2025
Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Background: "Patient Voices" is a software developed to promote the systematic collection of electronic patient-reported outcome measures (ePROMs) in routine oncology clinical practice.
Objective: This study aimed to assess compliance with and feasibility of the Patient Voices ePROM system and analyze patient-related barriers in an Italian comprehensive cancer center.
Methods: Consecutive patients with cancer attending 3 outpatient clinics and 3 inpatient wards were screened for eligibility (adults, native speakers, and being able to fill in the ePROMs) and enrolled in a quantitative and qualitative multimethod study.
Retina
January 2025
Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Purpose: To identify optical coherence tomography (OCT)-based imaging biomarkers that can localize focal leakage points without fluorescein angiography in central serous chorioretinopathy (CSC).
Methods: This retrospective case-control study analyzed 119 consecutive patients (123 eyes) with CSC between April 2018 and February 2024, comprising 66 eyes with focal-leakage type and 57 eyes with diffuse-leakage type. We assessed leakage sites using OCT, and the proportions of OCT findings were compared between focal- and diffuse-leakage types.
J Cardiovasc Med (Hagerstown)
February 2025
Center of Excellence in Cardiovascular Sciences, Ospedale Isola Tiberina, Gemelli Isola.
Aims: Coronary microvascular dysfunction (CMD) is a heterogeneous condition defined by reduced coronary flow reserve (CFR). The new index 'microvascular resistance reserve' (MRR) has been developed, but its role is unclear. We investigate the relationships between functional indices in ANOCA (angina and non-obstructive coronary arteries) patients and evaluate the hemodynamic features of different CMD subtypes.
View Article and Find Full Text PDFEur Thyroid J
January 2025
D Salvatore, Department of Public Health, University of Naples Federico II, Naples, Italy.
Objective: To analyse at our Institution the criteria for selecting a first-line therapy for patients with an advanced radioiodine-refractory thyroid cancer, their clinical responses, safety and survival outcomes.
Patients And Methods: We extracted data from 69 consecutive patients referred from September 2016 to September 2024 at Federico II University Hospital, among whom 44 patients were treated with TKIs as first line treatment and outside any clinical trial, and form the basis of this report.
Results: Thirty-one (71%) patients were treated with the antiangiogenesis inhibitor lenvatinib and 13 (29%) with selective tyrosine kinase inhibitors (s-TKIs).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!